statistiche per CROCI, STEFANIA

Distribuzione geografica

Continente	#
NA - Nord America	1263
EU - Europa	749
AS - Asia	376
AF - Africa	37
SA - Sud America	4
Continente sconosciuto - Info sul continente non disponibili	1
Totale	2430

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	1247
GB - Regno Unito	332
CN - Cina	170
VN - Vietnam	146
IT - Italia	93
UA - Ucraina	90
SE - Svezia	61
RU - Federazione Russa	56
IN - India	51
FR - Francia	47
ZA - Sudafrica	28
EE - Estonia	25
DE - Germania	24
CA - Canada	16
RO - Romania	7
SC - Seychelles	7
CH - Svizzera	6
CL - Cile	4
JP - Giappone	4
NL - Olanda	3
EG - Egitto	2
GR - Grecia	2
ID - Indonesia	2
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
ES - Italia	1
HR - Croazia	1
IR - Iran	1
PT - Portogallo	1
TR - Turchia	1
Totale	2430

Salva come PNG Salva come JPEG

Città	#
Southend	288
Fairfield	264
Woodbridge	125
Houston	120
Seattle	118
Wilmington	118
Ashburn	114
Ann Arbor	103
Dong Ket	87
Cambridge	82
Jacksonville	59
Westminster	32
Padova	29
Nanjing	28
Beijing	21
Bologna	18
Redwood City	18
Shenyang	17
Jinan	16
Ottawa	15
Saint Petersburg	15
Hebei	11
Nanchang	11
Changsha	10
Milan	10
San Diego	10
Guangzhou	8
Jiaxing	8
Tianjin	8
Dearborn	7
Kuban	7
Mahé	7
Zhengzhou	7
Moscow	6
Bulle	5
Redmond	4
Taizhou	4
Tokyo	4
Chieti	3
Ningbo	3
Phoenix	3
Taiyuan	3
Verona	3
Frankfurt Am Main	2
Haikou	2
Jakarta	2
Kunming	2
Lanzhou	2
Muizenberg	2
Ulan-ude	2
Amsterdam	1
Berlin	1
Bochum	1
Buffalo	1
Casoria	1
Cupertino	1
Dallas	1
Den Haag	1
Genzano Di Roma	1
Grizzana	1
Hamburg	1
Hangzhou	1
Henderson	1
Istanbul	1
Kherson	1
Kiev	1
Las Vegas	1
Leawood	1
Ludwigshafen	1
Napoli	1
North Bergen	1
Norwalk	1
Orange	1
San Jose	1
San Venanzo	1
Sant'elena	1
Toronto	1
Wenzhou	1
Xiangfen	1
Yuanping	1
Zanjan	1
Totale	1874

Salva come PNG Salva come JPEG

Nome	#
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome	133
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R	124
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.	104
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.	100
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.	95
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy	93
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity.	93
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role.	88
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor	83
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2.	83
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis	83
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.	83
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.	82
Immunological prevention of a multigene cancer syndrome	82
null	80
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.	78
Antimetastatic activity of a preventive cancer vaccine.	78
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines	77
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis	77
Toward the definition of immunosuppressive regimens with antitumor activity.	75
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine	71
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells	71
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.	67
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.	66
In silico modeling and in vivo efficacy of cancer preventive vaccinations	63
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system	63
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis.	61
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells	60
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy	59
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent	56
Isolation and in vitro differentiation of human Mesenchymal Stem Cells from new alternative sources: fetal membranes and placenta	51
Translational immunomics of cancer prevention.	48
null	7
Totale	2534

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	2534
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	2534

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2017/2018	72	0	0	0	0	5	2	0	0	0	0	65	0
2018/2019	262	11	27	0	42	5	27	11	16	29	37	19	38
2019/2020	1109	134	26	20	62	121	104	146	165	140	86	44	61
2020/2021	559	116	44	21	30	11	30	8	28	61	30	25	155
2021/2022	521	66	17	55	24	54	27	18	48	26	57	129	0
Totale													2534

CRIS Current Research Information System

statistiche per CROCI, STEFANIA